SCHEMBL231479

SCHEMBL231479

[CH2]CCC(=O)N(CC)CC

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.64
MMP1 P03956 1/20 0.42
MMP2 P08253 1/20 0.42
MMP3 P08254 1/20 0.42
MMP8 P22894 1/20 0.42
ALDH1A1 P00352 5/20 0.37
HPGD P15428 3/20 0.37
NPC1 O15118 1/20 0.34
TSHR P16473 1/20 0.34
RAB9A P51151 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
ALDH2 P05091 1/20 0.33
TSPO P30536 1/20 0.33
PTPN1 P18031 1/20 0.33
GLA P06280 1/20 0.33
RECQL P46063 1/20 0.33
HSD17B10 Q99714 1/20 0.32
CA12 O43570 1/20 0.32
CA1 P00915 1/20 0.32
CA9 Q16790 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5211497 0.86 ALDH1A1 (0.50) LMNAMMP1MMP2MMP3MMP8
SCHEMBL497604 0.85 LMNA (0.73) LMNAMMP1MMP2MMP3MMP8
SCHEMBL498180 0.83 LMNA (0.70) LMNAMMP1MMP2MMP3MMP8
SCHEMBL2327551 0.83 LMNA (0.78) LMNAMMP1MMP2MMP3MMP8
SCHEMBL5212139 0.83 CA12 (0.52) LMNAMMP1MMP2MMP3MMP8
SCHEMBL5211102 0.83 LMNA (0.45) LMNAMMP1MMP2MMP3MMP8
SCHEMBL7558507 0.81 LMNA (0.67) LMNAMMP1MMP2MMP3MMP8
SCHEMBL7554998 0.81 LMNA (0.67) LMNAMMP1MMP2MMP3MMP8
SCHEMBL7556079 0.81 LMNA (0.67) LMNAMMP1MMP2MMP3MMP8
SCHEMBL5542370 0.81 LMNA (0.67) LMNAMMP1MMP2MMP3MMP8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 173 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190117776-A1 Pharmaceutical Compositions of Fumaric Acid Esters HPS INVESTMENT PARTNERS, LLC, AS ADMINISTRATIVE AGENT 2019-04-25 US claimed
US-9999672-B2 Pharmaceutical compositions of fumaric acid esters XENOPORT, INC. (US) 2018-06-19 US claimed
US-20150265707-A1 PHARMACEUTICAL COMPOSITIONS OF FUMARIC ACID ESTERS HPS INVESTMENT PARTNERS, LLC, AS ADMINISTRATIVE AGENT 2015-09-24 US claimed
EP-2445877-A2 BICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME Nanotherapeutics, Inc. (US) 2012-05-02 EP claimed
US-20100197723-A1 BICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME NANOSHIFT, LLC 2010-08-05 US claimed
WO-2010065743-A2 BICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME NANOTHERAPEUTICS, INC. (US) 2010-06-10 WO claimed
CN-115175967-B Ionic liquids for stabilizing viscosity of silicate-based coatings 巴斯夫欧洲公司 2024-06-14 CN disclosed
CN-115175967-A Ionic liquids for stabilizing viscosity of silicate-based coatings 巴斯夫欧洲公司 2022-10-11 CN disclosed
US-11261155-B2 Urea derivative or pharmacologically acceptable salt thereof KYORIN PHARMACEUTICAL CO., LTD. (JP) 2022-03-01 US disclosed
US-11135296-B2 Pharmaceutical compositions of fumaric acid esters ARBOR PHARMACEUTICALS, LLC (US) 2021-10-05 US disclosed
US-20210107869-A1 Urea Derivative Or Pharmacologically Acceptable Salt Thereof KYORIN SEIYAKU KK (JP) 2021-04-15 US disclosed
US-10696630-B2 Urea derivative or pharmacologically acceptable salt thereof KYORIN PHARMACEUTICALS CO., LTD. (JP) 2020-06-30 US disclosed
US-10464891-B2 Urea derivative or pharmacologically acceptable salt thereof KYORIN PHARMACEUTICALS CO., LTD. (JP) 2019-11-05 US disclosed
EP-0200915-B1 AMINOPROPANOL DERIVATIVES, PROCESS FOR THEIR PREPARATION, THEIR USE AND MEDICINES CONTAINING THEM Roche Diagnostics GmbH (DE) 1989-09-27 EP disclosed
US-4863949-A CARDIOVASCULAR DISORDER TREATMENT BOEHRINGER MANNHEIM GMBH (DE) 1989-09-05 US disclosed
EP-0316668-A2 Use of a tetrahydro-pyrido(2,3-d)pyrimidine for obtaining an analgetic agent MERCK PATENT GmbH (DE) 1989-05-24 EP disclosed
EP-0280951-A1 Amino-propanol derivatives, process for their preparation and medicines containing these compounds, as well as intermediates Roche Diagnostics GmbH (DE) 1988-09-07 EP disclosed
US-4665066-A BACTERICIDES ELI LILLY AND COMPANY (US) 1987-05-12 US disclosed
EP-0200915-A1 Aminopropanol derivatives, process for their preparation, their use and medicines containing them Roche Diagnostics GmbH (DE) 1986-11-12 EP disclosed
EP-0140194-A2 Carbamoyltriazoles, and their production and use SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1985-05-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11135296-B2 Pharmaceutical compositions of fumaric acid esters FAH, FH, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 LMNA 2691/4885MMP1 3740/4885MMP2 2760/4885
US-10696630-B2 Urea derivative or pharmacologically acceptable salt thereof FPR1, FPR2, FPR3 LMNA 4414/4885MMP1 3565/4885MMP2 3886/4885
US-20150265707-A1 PHARMACEUTICAL COMPOSITIONS OF FUMARIC ACID ESTERS FAH, FH, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 LMNA 2691/4885MMP1 3740/4885MMP2 2760/4885
US-10464891-B2 Urea derivative or pharmacologically acceptable salt thereof FPR1, FPR2, FPR3 LMNA 4414/4885MMP1 3565/4885MMP2 3886/4885
US-20210107869-A1 Urea Derivative Or Pharmacologically Acceptable Salt Thereof FPR1, FPR2, FPR3 LMNA 4414/4885MMP1 3565/4885MMP2 3886/4885
US-20100197723-A1 BICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME HTR2C, HTR3A, HTR3C LMNA 3812/4885MMP1 4820/4885MMP2 4287/4885
US-20190117776-A1 Pharmaceutical Compositions of Fumaric Acid Esters FAH, FH, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 LMNA 2691/4885MMP1 3740/4885MMP2 2760/4885
US-11261155-B2 Urea derivative or pharmacologically acceptable salt thereof FPR1, FPR2, FPR3 LMNA 4414/4885MMP1 3565/4885MMP2 3886/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.